We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00332852
Recruitment Status : Completed
First Posted : June 2, 2006
Last Update Posted : February 23, 2017
Information provided by:

Brief Summary:

This is a prospective open-label one-arm phase III trial designed to evaluate the safety and efficacy of letrozole 2.5 mg administered orally daily for 24 months as adjuvant therapy in postmenopausal patients with primary breast cancer.

This trial is not recruiting patients in the United States.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Letrozole Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 655 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Phase III Trial With Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Study Start Date : March 2006
Primary Completion Date : July 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Letrozole
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Letrozole Drug: Letrozole
2.5 mg/day - oraly
Other Names:
  • Femara
  • FEM345

Primary Outcome Measures :
  1. Rate of patients without recurrence after 24 months of Letrozole treatment as assessed by radiological imaging [ Time Frame: after 24 months ]

Secondary Outcome Measures :
  1. Disease free survival (DFS) [ Time Frame: every 6 months for 24 months ]
  2. Quality of life as assessed by EORTC QLQ-C30 + BR23 every 3 months [ Time Frame: Every 6 months ]
  3. Safety and tolerability with assessments incuding biochemistry, hematology, ECG, pyhsical exam and AE documentation [ Time Frame: every 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Compliant postmenopausal women with primary operable breast cancer after complete surgery and suitable for endocrine treatment
  • Nodal status negative or positive
  • Good Health status 0-2 (Eastern Cooperative Oncology Group)
  • Estrogen- and/or progesterone-receptor positive
  • Adequate marrow, kidney and liver function

Exclusion criteria:

  • Metastatic or inflammatory breast cancer
  • Patients with previous or concomitant cancers (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell skin cancer or in situ cancer of the cervix. Patients with other previous cancers must have been disease-free for at least 5 years and Patients with uncontrolled, non-malignant systemic cardiovascular, kidney, and liver diseases.
  • Current/active dental problems including infection of the teeth or jawbone, dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures.
  • Recent (within 6 weeks) or planned dental or jaw surgery
  • Patients with primary overactive parathyroid
  • Patients with a known hypersensitivity to zoledronic acid or other bisphosphonates.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00332852

  Show 54 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmeceuticals

Additional Information:
Responsible Party: External Affairs, Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00332852     History of Changes
Other Study ID Numbers: CFEM345DDE10
First Posted: June 2, 2006    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017

Keywords provided by Novartis:
Postive breast cancer
disease free survival
early adjuvant treatment
primary hormone receptor

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs